Analyst consensus rating
Corvus Pharmaceuticals Analyst Rating: Strong Buy
Direct answer
Corvus Pharmaceuticals's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.14.
Forecast evidence checked October 18, 2026.
Get free Corvus Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.52
- Average price target
- $33.14
- High price target
- $42.00
- Low price target
- $27.00
- Low target gap
- +183.6%
- Target upside
- +248.1%
- High target gap
- +341.2%
- Target range width
- 157.6%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $33.14.
How far are Corvus Pharmaceuticals's low and high targets from the recorded price?
The low target implies +183.6%, while the high target implies +341.2%.
How many analysts are included in Corvus Pharmaceuticals's consensus?
The verified consensus includes 7 analysts.
How is Corvus Pharmaceuticals's target upside or downside calculated?
The average target of $33.14 is divided by the recorded price of $9.52, then one is subtracted to produce +248.1%. This does not guarantee a future return.
When was Corvus Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.